Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
This press release is being prepared.
The market announcement is already indexed, but the document has not finished syncing to our storage yet.